徐浩李成忠△ 尹伟张迁.恩替卡韦治疗HBeAg 阳性乙型肝炎临床观察[J].现代生物医学进展英文版,2011,11(11):2125-2127. |
恩替卡韦治疗HBeAg 阳性乙型肝炎临床观察 |
Clinical Observation of Entecavir in Treatment of HBeAg PositivePatients with Hepatitis B |
|
DOI: |
中文关键词: 乙型肝炎 恩替卡韦 拉米夫定 HBeAg 阳性 |
英文关键词: Hepatitis B Entecavir Lamivudine Positive HBeAg |
基金项目: |
|
Hits: 688 |
Download times: 1709 |
中文摘要: |
目的:探讨恩替卡韦治疗HBeAg 阳性乙型肝炎的疗效与安全性。方法:140 例慢性乙肝患者随机分为2 组:观察组予恩替卡
韦0.5 mg/d,对照组予拉米夫定100 mg/d,疗程均为48 周。观察两组HBV DNA 阴转率、ALT 复常率、HbeAg 血清转换率以及不
良反应发生情况。结果:在治疗12 周后,观察组与对照组HBV DNA 阴转率分别为47.1%、22.9% (P<0.01),ALT 复常率分别为
51.4%、31.4% (P<0.05),在治疗48 周后,观察组与对照组HBV DNA 阴转率分别为88.6%、48.6% (P<0.01),ALT 复常率分别为
90.0%、72.9% (P<0.01)。HbeAg 血清转换率无统计学差异,两组患者未见严重不良反应。结论:恩替卡韦治疗HBeAg 阳性乙肝患
者,较拉米夫定起效快、作用强,且安全性好。 |
英文摘要: |
Objective: To investigate efficacy and safety of entecavir on treatment of hepatitis B with positive HBeAg. Methods:
140 patients with chronic hepatitis B were randomly divided into 2 groups: study group were treated with entecavir 0.5 mg/d, and the
control group were given lamivudine 100 mg/d. Both of the course was 48 weeks. HBV DNA negative conversion rates, ALT normalization
rate, HBeAg seroconversion rates and incidence of adverse reactions were observed. Results: After 12 weeks of treatment, HBV
DNA negative conversion rate of the observation and control group were 47.1% and 22.9% (P <0.01), respectively. ALT normalization
rate were 51.4% and 31.4% (P <0.05), respectively. After 48 weeks of treatment, HBV DNA negative conversion rate of the observation
and control group were 88.6% and 48.6% (P <0.01), respectively. ALT normalization rate were 90.0% and 72.9% (P <0.01), respectively.
HBeAg seroconversion between the two groups were no significant difference. No serious adverse events occurred in the both groups.
Conclusion: Compared with lamivudine, entecavir shows more rapid onset, stronger efficacy, and safety on treatment of hepatitis B with
positive HBeAg. |
View Full Text
View/Add Comment Download reader |
Close |
|
|
|